QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
March 13, 2024 16:05 ET | Quoin Pharmaceuticals, Inc.
Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
March 13, 2024 07:55 ET | Catalyst Pharmaceuticals, Inc.
AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile Available in the U.S. by Prescription for...
azafaros_1x.png
Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients
March 12, 2024 02:00 ET | Azafaros BV
Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients Major milestone reached in bringing new treatment options to patients and...
QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
March 07, 2024 16:05 ET | Quoin Pharmaceuticals, Inc.
ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...
Biogen_Logo_Standard-rgb_R.jpg
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
March 06, 2024 07:30 ET | Biogen Inc.
New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZAReductions in biomarker complement...
QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering
March 05, 2024 08:00 ET | Quoin Pharmaceuticals, Inc.
ASHBURN, Va., March 05, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
March 04, 2024 08:00 ET | Quoin Pharmaceuticals, Inc.
Clearance to include teen patients in both the company’s open label and placebo controlled studies expected to significantly expand the number of eligible subjects, potentially expedite recruitment...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 28, 2024 18:03 ET | Catalyst Pharmaceuticals, Inc.
    Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022 Achieved Record Fourth Quarter 2023 Total Revenues of $110.6 Million, an 82.0% Increase Compared to...
zealand_logo_RGB_01.png
Zealand Pharma Announces Financial Results for the Full Year 2023
February 27, 2024 01:00 ET | Zealand Pharma
Company announcement - No. 9 / 2024 Zealand Pharma Announces Financial Results for the Full Year 2023 Significant progress delivered across our obesity and rare disease assets while building a...
tricha shivas (woman)
Tricha Shivas Promoted to Chief of Staff and Strategy at Foundation for Sarcoidosis Research
February 15, 2024 06:23 ET | Foundation for Sarcoidosis Research
The Foundation for Sarcoidosis Research (FSR) proudly announces the promotion of Tricha Shivas to Chief of Staff and Strategy.